Canada Markets closed

Entheon Biomedical Corp. (ENBI.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
Add to watchlist
0.0800+0.0050 (+6.67%)
At close: 03:19PM EDT
Full screen
Previous Close0.0750
Open0.0750
Bid0.0800 x N/A
Ask0.0850 x N/A
Day's Range0.0750 - 0.0850
52 Week Range0.0400 - 0.7100
Volume49,506
Avg. Volume36,837
Market Cap4.723M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.2160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. pursuant to an asset purchase agreement for a purchase price of CAD$1,000,000 (the "Transaction"). ...

  • Newsfile

    Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents

    Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for ...

  • GlobeNewswire

    Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

    AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med